Register before September 22nd & Save €100
With over 15 years’ experience in delivering award winning digitally enabled patient support programs, we provide end-to-end service design and delivery, from mapping unmet patient needs, to integrating digitally enhanced programs within tight brand timelines.
Our Affinial platform uses therapy specific behavior change models to deliver personalized interventions and support specific to each patient’s condition and circumstance. Improving patient self-management while ensuring scalability, greater consistency and better patient experience.
INC Research/inVentiv Health (Nasdaq:INCR) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to address new market realities where clinical and commercial share expertise, data and insights to accelerate biopharmaceutical performance. With more than 22,000 employees and the ability to support customers in more than 110 countries, our global scale and deep therapeutic alignment enables INC Research/inVentiv Health to help customers successfully navigate an increasingly complex environment. For more information on our Raleigh, N.C.-based company, visit incresearch.com or inventivhealth.com.
The company was ranked a “Top CRO to Work With” among the top 10 global CROs in the 2017 CenterWatch Global Investigative Site Relationship Survey. Our purpose is Shortening the Distance From Lab to LifeTM – creating better, smarter, faster ways to speed important therapies to market.
More information coming soon...
The patient will see you now!
Patients are more informed and more empowered than ever before to manage their health and quality of life.
Oxford PharmaGenesis is a HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups. We recognise that engaging with the patient perspective and communicating effectively with patients are key objectives for all healthcare stakeholders. Since our foundationin 1998, Oxford PharmaGenesis has been dedicated to improving patient health. Our mix of scientific rigour, engaging content and understanding of health literacy enables us to provide tailored communications that patients value. We are proud to play a role in supporting our clients to meet patients’ needs.
As an independent medical communications agency, we at Bedrock thrive on being long term authentic allies of our clients and being their strategic advisors: key to this success is having 3 core specialisms under one roof, embedding insights and multimedia in the medical communications journey.
Acting as audience ambassadors, we bring a profound understanding of the style and tone of communication to make an impact. We bring audiences to the forefront of our client’s communication plans, bridging the gap between all stakeholders, measuring changes in behaviour over time and adapting messages and delivery channels accordingly.
Bedrock combine a high level of scientific knowledge, market understanding and creativity enabling us to unearth the real challenges and opportunities each client and brief brings. We tailor the balance of these three key elements according to the needs of the programs.
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that customers can move ahead with confidence. With more than 40 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so we can adapt without compromising standards.
Powered by the company’s EXPERT® technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement, and measure the efficacy of new clinical treatments while ensuring patient safety. Since 2014, more than half of all FDA drug approvals came from ERT-supported studies. Pharma companies, biotechs, and CROs have relied on ERT solutions in 9,500+ studies spanning three million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly – and with confidence.
TransPerfect Life Sciences is the world's largest life sciences language services provider, with annual revenues of more than $550 million. With offices in over 90 cities worldwide, TransPerfect is the ideal partner to ensure that your global launch makes a global impact. More than 3,000 global organisations employ TransPerfect’s GlobalLink® Technology to simplify management of multilingual content. TransPerfect is fully ISO 9001:2015- and ISO 17100:2015-certified, with an unparalleled commitment to quality and client service. TransPerfect has global headquarters in New York, with regional headquarters in London and Hong Kong. For more information, please visit our website at www.transperfect.com
CheckOrphan is the leading news and information source for rare diseases and orphan products - no one offers you more. Choose from the latest news, videos, treatments, clinical trials, research, events and more about rare diseases and orphan drugs. CheckOrphan is also the first source to provide a database of Access Programs, essential for helping patients gain access to much needed treatments. CheckOrphan works with all entities that focus on rare diseases and orphan products. Sign up for your free daily newsletter and stay informed. Send us your news, events, videos and more so we can promote you (firstname.lastname@example.org) and follow us on Twitter, Facebook, Blog, YouTube, LinkedIn, and Google+
Evvnt - www.evvnt.com
Pf Magazine is for pharma professionals with the desire and potential to reach the top, featuring the latest industry news and thought-provoking features.
Pharma Marketing News is an independent monthly electronic newsletter focused on issues of importance to pharmaceutical marketing executives. It is a service of the Pharma Marketing Network -- The First Forum for Pharmaceutical Marketing Experts — which brings together pharmaceutical marketing professionals from manufacturers, communications companies, and marketing service providers for wide ranging discussions and education on a multitude of current topics. View the website here.
pharmaphorum media is the premier digital publisher of thought leadership relating to the pharmaceutical industry. The news, opinions and insights published every day help industry executives better understand the broader healthcare landscape within which they operate, including regular contributions from their peers, innovative service providers, physicians, payers / policy makers, patient organisations and patients. Core channels include www.pharmaphorum.com, our new digital journal Deep Dive and a highly engaged social media audience through multiple platforms.
Only 2 days left to save €100 with our Last Chance discount. Don't miss out!
eyeforpharma is a registered company in England and Wales - Registered number 09823909. 7-9 Fashion Street, London, E1 6PX, UK. Contact Us.
Website Development by Fruitbowl Media Ltd.